NASDAQ:NVCR - Novocure Stock Price, Forecast & News

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $0.02 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.07. The medical equipment provider earned $92.06 million during the quarter, compared to analysts' expectations of $87.12 million. Novocure had a negative net margin of 8.43% and a negative return on equity of 18.45%. The business's revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.13) earnings per share. View Novocure's Earnings History.

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Novocure.

Novocure will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Novocure updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

6 brokerages have issued 1-year target prices for Novocure's shares. Their forecasts range from $50.00 to $97.00. On average, they anticipate Novocure's share price to reach $80.33 in the next twelve months. This suggests that the stock has a possible downside of 13.2%. View Analyst Price Targets for Novocure.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Media coverage about NVCR stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Novocure earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Novocure.

Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), NuVasive (NUVA), Tandem Diabetes Care (TNDM), ICU Medical (ICUI) and Nevro (NVRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and NVIDIA (NVDA).

Novocure's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.35%), Peregrine Capital Management LLC (0.15%), Polianta Ltd (0.01%), Sciencast Management LP (0.01%), Nisa Investment Advisors LLC (0.00%) and IFP Advisors Inc (0.00%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Sciencast Management LP, Polianta Ltd, IFP Advisors Inc and Nisa Investment Advisors LLC. View Insider Buying and Selling for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $92.58.

Novocure has a market capitalization of $9.16 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

The official website for Novocure is http://www.novocure.com/.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]